Clinical Trial Application for LAE103 Approved by FDA
August 3, 2025
Source: drugdu
111
On July 31, Laekna Pharmaceuticals (02105) issued an announcement, announcing that its independently developed new drug LAE103 clinical trial (IND) application has been approved by the U.S. Food and Drug Administration (FDA).
LAE103 is a monoclonal antibody targeting ActRIIB with the potential to treat sarcopenia and other muscle-related diseases.
Source：https://finance.eastmoney.com/a/202507313472639341.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for marketing authorization of trivalent influenza virus split vaccine has been accepted October 8, 2025
- Walvax Biopharma’s vaccine receives Jordanian Drug Registration Certificate, marking a key step forward in its Middle East market expansion. October 8, 2025
- Zhifei Bio’s independent product, influenza virus split vaccine, has obtained a drug registration certificate October 8, 2025
- Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease October 7, 2025
- Large-scale analysis offers insights into sporadic nature of chikungunya virus outbreaks October 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
